TransMedics (NSDQ:TMDX) announced today that it received FDA premarket approval for its OCS Heart system.
Andover, Massachusetts-based TransMedics designed its OCS Heart system for use with organs from donors after brain death with indication for preserving donor hearts deemed unsuitable for procurement and transplantation at initial evaluation due to limitations of prolonged cold static cardioplegic preservation, according to a news release.